Shah Prem S purchased $2.0M of CVS

Shah Prem S (EVP and Group President) purchased 23,855 shares of CVS HEALTH Corp (CVS) at $83.90 ($2.00M total) on 2026-11-06.

Original reporting
SEC EDGAR · Shah Prem S
Published Nov 6, 2026, 9:41 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 9:44 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CVS
Bullish
high confidence
Mentioned
$CVS
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CVSBullishMed
01

Why it matters

The purchase adds to insider ownership, potentially influencing investor perception.

02

Market read

Insider buying is a positive signal that may support CVS stock in the short term.

03

What to watch

No disclosed 10b5-1 plan; the purchase may be opportunistic rather than strategic.

Relevance 7/10Novelty 6/10Timing: after market today

Background

SEC Form 4 filing discloses insider transactions for public companies.

Company-level read

Ticker impact

$CVSBullishHigh confidence
Context

EVP Shah Prem S bought 23,855 shares of CVS for $2.0M, increasing his stake to 88,516 shares.

Expected impact

likely upward pressure as the market prices in the insider buying.

Evidence & confidence

Form 4 filing is a primary source; the purchase size is material for an insider and signals positive sentiment.

Market effects

May reinforce confidence in the healthcare retail sector.

Limited to US markets where CVS trades.

Minimal global impact.

Counterpoint

Insider buying could be routine portfolio rebalancing, not a strong signal.

Key entities

  • Shah Prem S

    EVP and Group President at CVS Health Corp.

  • CVS Health Corp

    U.S. health services and retail pharmacy chain.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CVSHighAI 8/10

What Did CVS Health's Quarter Change For Its Stock?

CVS Health reported Q3 2026 earnings of $2.09 per share, beating estimates, with revenue at $108 billion. Despite this, its stock fell 12.5% on the day, while peers like Elevance Health rose. Operating income increased year-over-year to $3.57 billion. Management raised its 2026 EPS outlook and expects growth in 2027, but the Health Services segment faces challenges. CVS plans to split into two companies by mid-2028.

$CVSMed

CVS’ Decision to Split Retail Pharmacy and Healthcare Solutions Company May Affect Pricing for Customers

CVS is splitting its retail pharmacy business from its healthcare solutions and insurance operations. The company claims the two entities will operate independently, but experts have mixed views on potential drug pricing impacts. CVS Pharmacy will include 9,000 retail locations and MinuteClinic, while the healthcare solutions company will comprise Aetna and other health services.